Tests probiotics alongside usual treatment for ulcerative colitis and irritable bowel syndrome
Tests probiotics added to usual care in adults with ulcerative colitis or IBS.
Plain-language title generated from the registry record
Registry title: Efficacy of Probiotics in Patients With IBD
Key facts
- Where
- Xinxiang, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with ulcerative colitis or irritable bowel syndrome who can swallow probiotic pellets. They get usual treatment plus probiotics or usual treatment plus a placebo.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- A clinical diagnosis of ulcerative colitis or irritable bowel syndrome. The summary names mild to moderate ulcerative colitis and diarrhea-type irritable bowel syndrome.
Main reasons for not taking part
- Indeterminate colitis
- Suspected inflammatory bowel disease (IBD)
- Cannot swallow probiotic pellets as required
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05652621, who can take part
Where in China
- The First Affiliated Hospital of Xinxiang Medical CollegeXinxiang, ChinaContact: Yongmei Y QinTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The First Affiliated Hospital of Xinxiang Medical College
- Trial code
- NCT05652621
- Record updated
- 15 December 2022
- Original description
This research group plans to take patients with mild to moderate UC and diarrhea IBS diagnosed in the First Affiliated Hospital of Xinxiang Medical College as examples, and divide them into UC group and IBS group; Each group was randomly divided into two groups, namely, conventional treatment+probiotics group and conventional treatment+probiotics placebo group.Starting from the intervention of probiotics on intestinal flora to alleviate intestinal injury caused by UC and IBS patients, the indicators of intestinal flora, serum inflammatory factors, metabolites in vivo, intestinal barrier-related protein expression, and fecal short-chain fatty acid level were detected to explore the clinical efficacy, intestinal protective effect and mechanism of probiotics in adjuvant treatment of UC and IBS patients.To provide new methods and new ideas for refractory UC and IBS, so as to improve the cure rate of UC and IBS, reduce the recurrence rate, relieve the physical and mental pain and economic burden of patients, and provide new ideas for the development and utilization of functional probiotics. It also seeks biosafety evidence for the future use of probiotics in antibiotic environment.Read full original descriptionShow less
Clinical Efficacy and Mechanism of Probiotics in the Adjuvant Treatment of Ulcerative Colitis and Irritable Bowel Syndrome
This research group plans to take patients with mild to moderate UC and diarrhea IBS diagnosed in the First Affiliated Hospital of Xinxiang Medical College as examples, and divide them into UC group and IBS group; Each group was randomly divided into two groups, namely, conventional treatment+probiotics group and conventional treatment+probiotics placebo group.Starting from the intervention of probiotics on intestinal flora to alleviate intestinal injury caused by UC and IBS patients, the indicators of intestinal flora, serum inflammatory factors, metabolites in vivo, intestinal barrier-related protein expression, and fecal short-chain fatty acid level were detected to explore the clinical efficacy, intestinal protective effect and mechanism of probiotics in adjuvant treatment of UC and IBS patients.To provide new methods and new ideas for refractory UC and IBS, so as to improve the cure rate of UC and IBS, reduce the recurrence rate, relieve the physical and mental pain and economic burden of patients, and provide new ideas for the development and utilization of functional probiotics. It also seeks biosafety evidence for the future use of probiotics in antibiotic environment.
Inclusion: Clinical diagnosis of ulcerative colitis; Clinical diagnosis of irritable bowel; Can swallow probiotic pellets as required.
Exclusion: indeterminate colitis,suspected IBD.